Detalles de la búsqueda
1.
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Lancet;
389(10083): 2031-2040, 2017 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28342637
2.
Human regulatory B cells combine phenotypic and genetic hallmarks with a distinct differentiation fate.
J Immunol;
193(5): 2258-66, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25080484
3.
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
JAMA Dermatol;
160(3): 290-296, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38265821
4.
Evaluation of Clinical Relevance and Biological Effects of Antirituximab Antibodies in Patients With Pemphigus.
JAMA Dermatol;
158(8): 893-899, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35731529
5.
IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.
Biomedicines;
10(8)2022 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892674
6.
FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.
Front Immunol;
13: 863095, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35663943
7.
The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab.
Front Immunol;
13: 849790, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35371083
8.
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro.
Eur J Immunol;
40(10): 2686-91, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20809522
9.
Methods to Study the Transcriptome of Regulatory B Cells.
Methods Mol Biol;
2270: 295-305, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33479905
10.
Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen.
Front Immunol;
12: 666022, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34054835
11.
Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus.
J Invest Dermatol;
141(9): 2132-2140.e1, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33766510
12.
Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment.
Biomedicines;
9(10)2021 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34680528
13.
CD11c+ B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors.
Front Immunol;
11: 32, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32158442
14.
Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
JAMA Dermatol;
156(5): 545-552, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32186656
15.
Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
Front Immunol;
10: 1794, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31440235
16.
Long-Term Increase of Kcnn4 Potassium Channel Surface Expression on B Cells in Pemphigus Patients after Rituximab Treatment.
J Invest Dermatol;
138(12): 2666-2668, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30472996
17.
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
Sci Transl Med;
5(175): 175ra30, 2013 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-23467561
Resultados
1 -
17
de 17
1
Próxima >
>>